Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Combination of DNA-HIV-PT123 and AIDSVAX®B/Ein HIV-1-uninfected Adult Participants With or Without Underlying Schistosoma Mansoni Infection

NCT02376582 is registered in ClinicalTrials.gov with EuroVacc Foundation as lead sponsor.

NCT NCT02376582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02376582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Combination of DNA-HIV-PT123 and AIDSVAX®B/Ein HIV-1-uninfected Adult Participants With or Without Underlying Schistosoma Mansoni Infection
Lead sponsor
EuroVacc Foundation
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2014
Completion date
January 31, 2016
Enrollment
72 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv/aids